Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.

Patel D, Walitt B, Lindsay J, Wilensky RL.

JACC Cardiovasc Interv. 2011 Mar;4(3):353-60. doi: 10.1016/j.jcin.2010.10.016.

2.

Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner.

Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y.

Basic Res Cardiol. 2011 May;106(3):431-46. doi: 10.1007/s00395-011-0162-3. Epub 2011 Mar 1.

PMID:
21360043
3.

Conditional PPARγ knockout from cardiomyocytes of adult mice impairs myocardial fatty acid utilization and cardiac function.

Luo J, Wu S, Liu J, Li Y, Yang H, Kim T, Zhelyabovska O, Ding G, Zhou Y, Yang Y, Yang Q.

Am J Transl Res. 2010 Oct 1;3(1):61-72.

4.
5.

PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation.

Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ.

J Clin Invest. 2010 Oct;120(10):3443-54. doi: 10.1172/JCI40905. Epub 2010 Sep 13. Erratum in: J Clin Invest. 2010 Dec 1;120(12):4583.

6.

An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart.

Fang X, Palanivel R, Cresser J, Schram K, Ganguly R, Thong FS, Tuinei J, Xu A, Abel ED, Sweeney G.

Am J Physiol Endocrinol Metab. 2010 Nov;299(5):E721-9. doi: 10.1152/ajpendo.00086.2010. Epub 2010 Aug 24.

7.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
8.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
9.

Review article: Thiazolidinediones and heart failure.

Chaggar PS, Shaw SM, Williams SG.

Diab Vasc Dis Res. 2009 Jul;6(3):146-52. doi: 10.1177/1479164109338772. Review.

PMID:
20368206
10.

The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.

Ren L, Li Y, Li Y, Tang R, Hu D, Sheng Z, Liu N.

Cell Biochem Funct. 2010 Jan;28(1):58-65. doi: 10.1002/cbf.1621.

PMID:
20029960
11.

Transcriptional factors that promote formation of white adipose tissue.

White UA, Stephens JM.

Mol Cell Endocrinol. 2010 Apr 29;318(1-2):10-4. doi: 10.1016/j.mce.2009.08.023. Epub 2009 Sep 4. Review.

12.

Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.

Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.

Clin Exp Pharmacol Physiol. 2009 May;36(5-6):478-86. doi: 10.1111/j.1440-1681.2008.05088.x. Epub 2008 Oct 8.

PMID:
19673929
13.

PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.

Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, Wu Z.

Vascul Pharmacol. 2009 Aug-Sep;51(2-3):169-74. doi: 10.1016/j.vph.2009.06.004. Epub 2009 Jun 21.

PMID:
19540934
14.

Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome.

Marfella R, Di Filippo C, Portoghese M, Barbieri M, Ferraraccio F, Siniscalchi M, Cacciapuoti F, Rossi F, D'Amico M, Paolisso G.

J Lipid Res. 2009 Nov;50(11):2314-23. doi: 10.1194/jlr.P900032-JLR200. Epub 2009 May 24.

15.

Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.

Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J.

Arch Biochem Biophys. 2008 Sep 1;477(1):86-91. doi: 10.1016/j.abb.2008.05.015. Epub 2008 May 28.

PMID:
18541139
16.

Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study.

McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS.

Circulation. 2007 Sep 4;116(10):1170-5. Epub 2007 Aug 13.

17.

Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.

Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q.

Cardiovasc Res. 2007 Nov 1;76(2):269-79. Epub 2007 Jul 4.

PMID:
17678635
18.

Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma.

Ding G, Qin Q, He N, Francis-David SC, Hou J, Liu J, Ricks E, Yang Q.

J Mol Cell Cardiol. 2007 Jul;43(1):73-84. Epub 2007 Apr 27.

19.

Adiposity of the heart, revisited.

McGavock JM, Victor RG, Unger RH, Szczepaniak LS; American College of Physicians and the American Physiological Society..

Ann Intern Med. 2006 Apr 4;144(7):517-24. Review.

PMID:
16585666
20.

Lipotoxicity in the heart.

Borradaile NM, Schaffer JE.

Curr Hypertens Rep. 2005 Dec;7(6):412-7. Review.

PMID:
16386196

Supplemental Content

Support Center